Tests donor immune cell addback to prevent infections after stem cell transplant
Tests donor immune cells added back after transplant in children with leukemia or lymphoma.
Key facts
- Who runs it
- Children's Hospital of Philadelphia
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 100 people, planned
- Started
- 21 Mar 2025
- Expected to end
- Mar 2032
- Type of study
- Interventional, 3 groups
- Treatments tested
- Phase 1 Dose Level 1
- Phase 1 Dose Level 2
- Phase 1 Dose Level 3
- Phase 2 Maximum Tolerated Dose determined in Phase 1
- Phase 2 Established Dose from prior study, NCT03810196
- Record updated
- 15 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people up to 25 years old with blood cancers, bone marrow failure or immune disorders who need a stem cell transplant from a donor who is not a fully matched sibling.
- Age
- From 1 Month to 25 Years.
- Sex
- All sexes can join.
- Disease stage
- A disease for which a donor stem cell transplant may remove the disease. Blood cancer remission status follows the transplant program's standard practice. Conditions include high risk leukemia, relapsed leukemia, MDS, relapsed non-Hodgkin lymphoma, aplastic anemia, inherited bone marrow failure and immune disorders.
- Earlier treatment
- No planned alemtuzumab during conditioning.
- Biomarker or test result
- The donor needs a tissue type test. A related donor must be at least 5/10 HLA matched. An unrelated donor must be 9/10 or 10/10.
Main reasons for not taking part
- Performance score less than 60
- No donor available for mobilized peripheral stem cells
- Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma
- Has an available 10/10 HLA matched sibling donor
- Does not meet the center's disease, organ or infection criteria
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Disease for which allogeneic HSCT may be curative
- Remission status of hematologic malignancies and additional disease-specific eligibility determinations will be according to standards of practice within the CHOP Cellular Immunotherapy and Transplant Program (CTTS)
- Patients must be 25 years of age and less
- Evaluation for organ and infectious status as per our CTTS standard operating procedure
- Signed consent by parent/guardian or able to give consent if 18 years of age and older
- Participants of childbearing potential must have a negative pregnancy test as per institutional SOP
Who cannot take part
- HLA testing/matching; HLA testing to be done by molecular methods for A, B, C, DRB1, DQB1; Related donor: Must be ≥ 5/10 match; Unrelated donor: 10/10 or 9/10 match; KIR typing for haploidentical donor for hematologic malignancies; Donor specific HLA antibodies (DSA) should be assessed for all subjects receiving an HLA mismatched graft (≤ 9/10)
- Patients who do not meet institutional disease, organ or infectious criteria; Donor selection and eligibility:
- Patients who have performance score less than 60
- No suitable donor available for mobilized peripheral stem cells
- Patients with Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma
- Planned receipt of alemtuzumab during conditioning
- Patients with an available 10/10 HLA matched sibling donor
- Unrelated donor meets National Marrow Donor Program criteria for donation
- Related donor (at least haploidentical) willing and able to donate mobilized peripheral stem cells
- Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection
- Donors must be willing to sign consent to participate in this study
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Megan AtkinsonTaking people
About the trial
What the trial wants to find out
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.
The 3 groups in the trial
- Phase 1:TCRab/CD19 depleted PSCT with CD45RA depleted addback using mismatched related donors (MMRD)Treatment being tested
Stem cell source: mobilized peripheral blood stem cells (PBSC) Donor type: \> or = 5/10 mismatched related donor Conditioning: disease specific standard of care (SOC) regimens
Treatment: Phase 1 Dose Level 1, Phase 1 Dose Level 2, and Phase 1 Dose Level 3
- Phase 2:TCRab/CD19 depleted PSCT with CD45RA depleted addback at MTD found in phase 1 using MMRDTreatment being tested
Stem cell source: mobilized PBSC Donor type: \> or = 5/10 mismatched related donor Conditioning: disease specific SOC regimens
Treatment: Phase 2 Maximum Tolerated Dose determined in Phase 1
- Phase 2:TCRab/CD19 depleted PSCT with CD45RA depleted addback using unrelated donorsTreatment being tested
Stem cell source: mobilized PBSC Donor type: 9/10 or 10/10 matched unrelated donor Conditioning: disease specific SOC regimens
Treatment: Phase 2 Established Dose from prior study, NCT03810196
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant
- Plain-language title
- Tests donor immune cell addback to prevent infections after stem cell transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 April 2026